Navigation Links
Smith & Nephew Encouraged by United Kingdom NPWT Patent Court Decision
Date:5/1/2009

HULL, England, May 1 /PRNewswire-FirstCall/ -- Smith & Nephew's Advanced Wound Management business (LSE: SN; NYSE: SNN) announces that the Patents Court, in the High Court of Justice of England and Wales, has ruled as invalid 7 out of the 10 claims asserted against Smith & Nephew of the Negative Pressure Wound Therapy (NPWT) patent EP 0620720, that is licensed to Kinetic Concepts, Inc. (KCI) (NYSE: KCI). The 3 other claims asserted in the patent remain in effect in the United Kingdom. The decision is subject to appeal and Smith & Nephew will be pursuing its appeal to invalidate those three claims as a matter of urgency.

Smith & Nephew is pleased that this judgement has invalidated the main claim of the EP 0620720 patent. This complements the German decision of March 2009 where at the Federal Munich Patent Court the court ruled (subject to appeal) that all claims of the patent are invalid.

"We will continue to serve the United Kingdom NPWT market and offer the new RENASYS(TM) EZ, RENASYS(TM) GO and RENASYS(TM)- G (gauze) NPWT products. Smith & Nephew remains committed to our strategy to ensure that clinicians have a range of treatment options. This ruling has no impact on Smith & Nephew's ability to sell gauze-based NPWT systems, and we will continue our efforts to ensure that clinicians have options in NPWT. We intend to pursue the remaining asserted claims as a matter of urgency," said Robin Carlstein, Senior Vice President of Advanced Wound Devices at Smith & Nephew.

    Inquiries
    Investors & Analysts
    Liz Hewitt                   +44 (0)20 7401 7646
    Group Director Corporate Affairs
    Smith & Nephew


    Media
    Robin Carlstein              +1 727 399 3746
    Senior Vice President Advanced Wound Devices Smith & Nephew

About Smith & Nephew

Smith & Nephew is a global medical technology business, specializing in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were nearly $3.8 billion.

(TM) Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward- looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


'/>"/>
SOURCE Smith & Nephew
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Smithfield Foods Sends Letter to Employees
2. Center to Expose and Close Animal Factories to Hold Media Teleconference Tomorrow to Discuss Smithfield Operations, Connection to Swine Flu, Health and Enviro Impacts
3. Smithfield Foods Says North American Influenza Not Present in Any of Its Worldwide Operations and Pork is Safe to Eat
4. Richard E. Smith, M.D., Installed as President of Michigan State Medical Society
5. New Evidence Supports Efficacy and Value of Smith & Nephew NPWT Products
6. NeuroFocus Appoints Dr. Michael Smith as Partner in Consulting Practice
7. GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
8. Smith & Wesson Security Services Wins Top Honors at SAMMY awards
9. New Coaching Program Helps Charge Nurses Develop Leadership Skills: B. E. Smith's Coaches Develop High Performers Who Improve Hospital Finances
10. Houlihan Smith to Host Illinois Venture Capital Association Luncheon Seminar on Midwest Healthcare Investing
11. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn from ... will show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , ... of pharmaceutical products, garnering increased attention from all stakeholders in the development of ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016   National Community Pharmacists Association ... MBA issued the following statement today in response to ... the Centers for Medicare & Medicaid Services (CMS) ... beneficiary advocates and others: patient advocacy organizations ... still reviewing the full CMS analysis. Our initial reaction ...
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas S.A. ... cash tender offer (the "Tender Offer") to purchase ... aggregate principal amount of its 6.500% Senior Notes ... Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection with ... "Consent Solicitation") consents (the "Consents") of the holders ...
Breaking Medicine Technology: